Johnson & Johnson

Explore the latest insights on Johnson & Johnson and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Johnson & Johnson’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Johnson & Johnson and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Johnson & Johnson's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

Wuhan Tangzhi Pharmaceutical Co., Ltd., a high‑technology developer and manufacturer of sugars, nucleic acids, and their derivatives, announced that it has raised nearly RMB 100 million (≈ US$14 million) in…

Allist Pharmaceuticals' NDA Accepted by China's CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

Allist Pharmaceuticals’ NDA Accepted by China’s CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma

CompanyLegal / IP

Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar

CompanyDrug

Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices

CompanyDeals

Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority

CompanyDrug

Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB

CompanyDrug

Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study

CompanyDeals

Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions

CompanyDrug

Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma

Show More